Last updated 2026-09-02
- Raised $200M Follow-on PO, Aug 2026
- Raised $100M Follow-on PO, Jun 2026
- Raised $60M Follow-on PO, May 2025
Total raised
$420.7M
Stage
—
Founded
2020
Headcount
13
HQ
Fort Lee, United States
Sector
Biotechnology
About
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious conditions with unmet medical needs in oncology and complement-related conditions. The company's pipeline includes NXP100, a complement Factor B inhibitor, and two kinase inhibitors, NXP900 and NXP200, for advanced cancers. Nuvectis Pharma operates with a capital-efficient, virtual business model, in-licensing promising therapeutics and advancing them through clinical development.
Funding history · 7 rounds · $420.7M total
7 events/rounds · $420.7M Total Funding: $15.3M in Private Equity, $405.4M in Public Equity
Aug 2026
Follow-on PO
$200.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2026
Follow-on PO
$100.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2025
Follow-on PO
$60.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2025
Follow-on PO
$13.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2022
PIPE
$15.9M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2022
Follow-on PO
$16.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2021
★ Sixth Element CapitalCRT Pioneer Fund
Headcount over time
13 employees (2026-09) · 1 point
Offices
Fort Lee, United States · HQ / main office
Q&A
- When was Nuvectis Pharma Inc. founded?
- Nuvectis Pharma Inc. was founded in 2020.
- What is Nuvectis Pharma Inc.'s primary sector?
- Nuvectis Pharma Inc.'s primary sector is Healthcare, specifically Biotechnology, Biopharmaceuticals, and Oncology/Cancer Treatment.
- Who are the co-founders of Nuvectis Pharma Inc.?
- The co-founders of Nuvectis Pharma Inc. are Ron Bentsur, Enrique Poradosu, and Shay Shemesh.
- What is Nuvectis Pharma Inc.'s business model?
- Nuvectis Pharma Inc. operates with a capital-efficient, virtual business model, in-licensing promising therapeutics and advancing them through clinical development.
- When did Nuvectis Pharma Inc. complete its Series A funding round and who were the lead investors?
- In August 2021, Nuvectis Pharma Inc. completed an A Round totaling $15,300,000. The lead investors were CRT Pioneer Fund and Sixth Element Capital.
- When did Nuvectis Pharma Inc. go public?
- Nuvectis Pharma Inc. completed an IPO in February 2022, raising $16,000,000.
- What was the amount raised in Nuvectis Pharma Inc.'s PIPE financing round?
- In July 2022, Nuvectis Pharma Inc. raised $15,900,000 through a PIPE financing round.
- What was the most recent follow-on public offering by Nuvectis Pharma Inc.?
- Nuvectis Pharma Inc. completed a follow-on public offering in August 2026, raising $200,000,000.
- What is the total amount of funding raised by Nuvectis Pharma Inc.?
- Nuvectis Pharma Inc. has raised a total of $420,700,000 across all funding rounds.
Team · 8
Ron Bentsur
Founder · Chairman, Chief Executive Officer and President
Enrique Poradosu
Founder · Chief Scientific and Business Officer
Shay Shemesh
Founder · Chief Development and Operations Officer
Michael Carson
Vice President of Finance
Ken Hoberman
Director
Matthew L. Kaplan
Director
James F. Oliviero, III
Director
Juan Sanchez
Director
Sectors & technology
Primary sector
Biotechnology
Technologies
Business model
Biopharmaceutical
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nuvectis.com |
|---|
Identifiers & details
| Legal name | Nuvectis Pharma, Inc. |
|---|---|
| Founded | 2020 |
| Employees (exact) | 13 |
Radar intelligence
Patents
| EPO | 4 |
|---|
Web history (Wayback)
| Domain | nuvectis.com |
|---|